Osteoporosis affects an estimated 500 million people globally, predisposing to fragility fractures that carry high morbidity and mortality, particularly hip fractures in older adults. Anti-resorptive therapy with bisphosphonates and denosumab, and anabolic agents romosozumab and teriparatide, form the pharmacological armamentarium. Sequential therapy strategies and fracture liaison service implementation are the focus of contemporary guideline development.
Bisphosphonate Interruption Reduces Fragility Fracture Risk
A nested case-control and cohort study in England found that interrupting bisphosphonate therapy after 3 or 5 years reduced fragility fracture risk.
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
A 12-month course of romosozumab significantly increases bone mineral density in postmenopausal women with osteoporosis.
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.
Opportunistic Osteoporosis Screening from CT Scans A Validated Approach?
Using cranial CT scans for opportunistic osteoporosis screening shows promise, but concerns remain. Addressing methodological criticisms is essential for validating this approach in broader clinical practice.
Can Routine CT Scans Predict Osteoporosis Risk?
Opportunistic osteoporosis screening using cranial CT scans could identify patients at high risk of major osteoporotic fractures without additional radiation. But workflow integration and cost-effectiveness remain open questions.